uniQure Seeks US Approval For Gene Therapy
Dutch developer uniQure has applied for US approval of its experimental gene therapy for Huntingtons disease. The submission follows an FDA reversal on trial data requirements, lifting company shares.
Xurve View
Insights:
Xurve View
uniQure has filed for United States approval of its experimental Huntington's disease gene therapy, pushing shares up 5% in premarket trading on Wednesday morning. The application follows an FDA reversal on trial data sufficiency after months of regulatory friction. The treatment aims to slow progression of the rare brain disorder, for which no approved disease-modifying drugs currently exist.
